Physician profile
Jonathan E Sollinger
NPI 1538235791
$3,021.69
in general payments reported to CMS, 2019-2025
25 companies · $625 in 2025
The $625 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $118 · 2021: $119 · 2022: $589 · 2023: $654 · 2024: $578 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,857.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $732.86 | 2019-2025 | Dyanavel Xr |
| Corium, LLC | $696.03 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $226.59 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Sanofi Pasteur INC. | $201.12 | 2019-2025 | |
| Glaxosmithkline, LLC. | $161.57 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Takeda Pharmaceuticals U.S.A., INC. | $134.67 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $123.69 | 2020-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $121.45 | 2021-2025 | Qelbree, Qelbree |
| Kaleo, INC. | $101.65 | 2021-2024 | Auvi-Q |
| Pfizer INC. | $73.61 | 2023-2024 | |
| Collegium Pharmaceutical, INC. | $73.01 | 2025 | Jornay Pm |
| Alexion Pharmaceuticals, INC. | $67.44 | 2024-2025 | Koselugo |
| Globus Medical, INC. | $41.88 | 2024 | Creo 5.5 |
| Shire North American Group INC | $33.60 | 2019 | |
| Sobi, INC | $31.82 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $28.34 | 2025 | |
| Qol Medical, LLC | $27.55 | 2023 | Sucraid |
| Neos Therapeutics, LP | $26.16 | 2019-2023 | Adzenys Xr-Odt |
| Mission Pharmacal Company | $19.26 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $18.18 | 2019 | |
| Genentech USA, INC. | $17.92 | 2020 | |
| Verrica Pharmaceuticals INC. | $17.34 | 2025 | Ycanth |
| Avion Pharmaceuticals | $17.18 | 2023 | Methylphenidate Hydrochloride |
| Glenmark Therapeutics INC. | $15.00 | 2019 | |
| Adlon Therapeutics L.P. | $13.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Sollinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.